MYGN MYRIAD GENETICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, MYRIAD GENETICS INC reported revenue of $191M (down 10.5% from a year earlier), net income of −$43.2M and diluted EPS of −$0.46; over the last four quarters revenue was $807M and net income −$113M; for the fiscal year ended December 2025 revenue was $825M, down 1.6% on the year before.
MYGN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $825M, gross profit $577M, operating income −$387M, net income −$366M (margin -44.4%), EPS −$3.95
- Fiscal year ended Dec 2024: revenue $838M, gross profit $585M, operating income −$124M, net income −$127M (margin -15.2%), EPS −$1.41
- Fiscal year ended Dec 2023: revenue $753M, gross profit $517M, operating income −$257M, net income −$263M (margin -34.9%), EPS −$3.18
- Fiscal year ended Dec 2022: revenue $678M, gross profit $476M, operating income −$141M, net income −$112M (margin -16.5%), EPS −$1.39
- Fiscal year ended Dec 2021: revenue $691M, gross profit n/a, operating income −$191M, net income −$27.0M (margin -3.9%), EPS −$0.35
MYGN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $191M (down 10.5% year over year), net income −$43.2M, EPS −$0.46
- Quarter ended Mar 31, 2026: revenue $200M (up 2.3% year over year), net income −$34.1M, EPS −$0.36
- Quarter ended Dec 31, 2025 (from the annual report): revenue $210M (down 0.4% year over year), net income −$8.00M, EPS −$0.09
- Quarter ended Sep 30, 2025: revenue $206M (down 3.6% year over year), net income −$27.4M, EPS −$0.29
- Quarter ended Jun 30, 2025: revenue $213M (up 0.8% year over year), net income −$331M, EPS −$3.57
- Quarter ended Mar 31, 2025: revenue $196M (down 3.1% year over year), net income −$100K, EPS $0.00
- Quarter ended Dec 31, 2024 (from the annual report): revenue $211M (up 7.1% year over year), net income −$42.2M, EPS −$0.47
- Quarter ended Sep 30, 2024: revenue $213M (up 11.2% year over year), net income −$22.1M, EPS −$0.24
- Quarter ended Jun 30, 2024: revenue $212M (up 15.3% year over year), net income −$36.7M, EPS −$0.41
- Quarter ended Mar 31, 2024: revenue $202M (up 11.6% year over year), net income −$26.0M, EPS −$0.29
- Quarter ended Dec 31, 2023 (from the annual report): revenue $197M (up 10.6% year over year), net income −$30.9M, EPS −$0.34
- Quarter ended Sep 30, 2023: revenue $192M (up 22.7% year over year), net income −$61.3M, EPS −$0.75
- Quarter ended Jun 30, 2023: revenue $184M (up 2.3% year over year), net income −$116M, EPS −$1.42
- Quarter ended Mar 31, 2023: revenue $181M (up 9.9% year over year), net income −$54.7M, EPS −$0.67
- Quarter ended Dec 31, 2022 (from the annual report): revenue $178M (up 10.6% year over year), net income −$42.3M, EPS −$0.52
- Quarter ended Sep 30, 2022: revenue $156M (down 6.5% year over year), net income −$35.1M, EPS −$0.43
- Quarter ended Jun 30, 2022: revenue $179M (down 5.3% year over year), net income −$14.1M, EPS −$0.18
- Quarter ended Mar 31, 2022: revenue $165M (down 4.7% year over year), net income −$20.5M, EPS −$0.26
- Quarter ended Dec 31, 2021 (from the annual report): revenue $161M, net income −$7.40M, EPS −$0.07
- Quarter ended Sep 30, 2021: revenue $167M, net income $24.6M, EPS $0.30
MYGN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $1.80M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$8.70M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$111M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$106M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow $18.6M, share buybacks $0
MYGN balance sheet
- Jun 30, 2026: cash $115M, total assets $639M, total liabilities $335M, shareholders' equity $304M, long-term debt $121M
- Mar 31, 2026: cash $124M, total assets $674M, total liabilities $336M, shareholders' equity $337M, long-term debt $120M
- Dec 31, 2025: cash $150M, total assets $707M, total liabilities $339M, shareholders' equity $368M, long-term debt $120M
- Sep 30, 2025: cash $145M, total assets $728M, total liabilities $355M, shareholders' equity $373M, long-term debt $120M
- Jun 30, 2025: cash $74.4M, total assets $677M, total liabilities $289M, shareholders' equity $388M, long-term debt $0
- Mar 31, 2025: cash $91.8M, total assets $1.01B, total liabilities $301M, shareholders' equity $705M, long-term debt $59.3M
- Dec 31, 2024: cash $102M, total assets $1.03B, total liabilities $327M, shareholders' equity $701M, long-term debt $39.6M
- Sep 30, 2024: cash $99.9M, total assets $1.08B, total liabilities $350M, shareholders' equity $732M, long-term debt $39.0M
What is MYGN's revenue?
MYRIAD GENETICS INC reported $807M of revenue over its last four quarters, through June 30, 2026.
Is MYGN profitable?
No. MYRIAD GENETICS INC lost $113M over the last four quarters.
What is MYGN's EPS?
Diluted earnings per share over the last four quarters were −$1.20; −$0.46 in the latest quarter.